In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by Audrey Gibson, PA-C, for part three of their special RhAPP Up series covering key psoriatic arthritis updates from the 2026 EULAR Congress.

They begin by discussing real-world evidence on long-term treatment persistence with advanced therapies in psoriatic arthritis, highlighting how different mechanisms of action compare over time. The conversation focuses on what persistence and discontinuation rates may reflect in clinical practice and how real-world data can help inform treatment decisions.

The episode also reviews a phase 2B study of a selective TYK2 inhibitor, exploring its effects on inflammatory biomarkers and clinical response in patients with active psoriatic arthritis. The discussion highlights how emerging biomarker research may one day help guide more personalized treatment selection and improve outcomes.

Whether you're a rheumatology provider, advanced practice provider (APP), or other healthcare professional, this episode offers practical insights into real-world treatment patterns, emerging targeted therapies, and the future potential of biomarker-driven precision medicine in psoriatic arthritis care.

Thank you for watching, be sure to explore the three-part ILD RhAPP Up Series, and stay tuned for our upcoming Osteoporosis Abstract Reviews.

In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by Audrey Gibson, PA-C, for part two of their special RhAPP Up series covering key psoriatic arthritis updates from the 2026 EULAR Congress.

They discuss new long-term data highlighting the durability of response with emerging therapies in psoriatic arthritis, including how patients who respond early may be able to maintain disease control over several years. The conversation focuses on what sustained efficacy means for real-world treatment decisions and long-term disease management.

The episode also reviews subgroup data from a phase 3 study of an IL-23–targeting therapy, showing consistent improvements in joint symptoms and inhibition of structural damage progression across a range of patient types. The discussion highlights the importance of early inflammation control and its role in reducing long-term joint damage.

Whether you're a rheumatology provider, advanced practice provider (APP), or other healthcare professional, this episode offers practical insights into long-term treatment outcomes, emerging biologic therapies, and key factors that may influence therapy selection in psoriatic arthritis care.

Stay tuned for part three of the RhAPP Up series and visit the Content Rheum to stay up to date with the latest clinical insights in rheumatologic care.

In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by Audrey Gibson, PA-C, as they kick off the first episode of a special three-part RhAPP Up series focused on key psoriatic arthritis updates from the 2026 EULAR Congress.

They discuss several key abstracts from the meeting, including a head-to-head trial comparing two different therapeutic approaches in active psoriatic arthritis and what the results may mean for treatment decisions in clinical practice. The conversation highlights how new data may help guide therapy selection and improve patient care.

The episode also reviews emerging data on a novel IL-17A inhibitor and its impact on patient-reported outcomes, including pain, fatigue, physical function, and quality of life. The conversation emphasizes the importance of aligning treatment goals with what matters most to patients, not just traditional clinical endpoints.

Whether you're a rheumatology provider, advanced practice provider (APP), or other healthcare professional, this episode offers practical insights into evolving psoriatic arthritis treatment strategies, emerging biologic therapies, and the growing emphasis on precision medicine in inflammatory arthritis care.

Stay tuned for Part 2 of the RhAPP Up series and visit the Content Rheum to stay up to date with the latest clinical insights in rheumatologic care.